Quinacrine promotes replication and conformational mutation of chronic wasting disease prions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 16, 2014, Pages 6028-6033

  Bian, Jifeng ^a   Kang, Hae Eun ^a   Telling, Glenn C ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Prion enhancing drugs; Prion therapeutics

Indexed keywords

MEPACRINE; PRION PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CHRONIC WASTING DISEASE AGENT; CONFORMATIONAL TRANSITION; DRUG ACTIVITY; DRUG EFFECT; GENE REPLICATION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

PRION ENHANCING DRUGS; PRION THERAPEUTICS;

ANIMALS; CELL LINE; CELL SURVIVAL; DEER; HUMANS; MICE; MUTATION; PRION DISEASES; PRIONS; PROTEIN CONFORMATION; PRPSC PROTEINS; QUINACRINE; WASTING DISEASE, CHRONIC;

EID: 84899061749     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322377111     Document Type: Article

References (62)

1. Lu D, et al. (2013) Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice. J Pharmacol Exp Ther 347(2):325-338.
2. Li Z, et al. (2013) Discovery and preliminary SAR of arylpiperazines as novel, brain-penetrant antiprion compounds. ACS Med Chem Letters 4(4):397-401.
3. Kimata A, et al. (2007) New series of antiprion compounds: Pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation. J Med Chem 50(21):5053-5056. (Pubitemid 47585702)
4. Geissen M, et al. (2011) From high-throughput cell culture screening to mouse model: Identification of new inhibitor classes against prion disease. ChemMedChem 6(10):1928-1937.
5. Ghaemmaghami S, May BC, Renslo AR, Prusiner SB (2010) Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol 84(7):3408-3412.
6. Nicoll AJ, et al. (2010) Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci USA 107(41):17610-17615.
7. Kuwata K, et al. (2007) Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci USA 104(29):11921-11926. (Pubitemid 47185606)
8. Doh-Ura K, Iwaki T, Caughey B (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74(10):4894-4897. (Pubitemid 30237920)
9. Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98(17):9836-9841. (Pubitemid 32769390)
10. Mead S, et al. (2011) PRION-1 scales analysis supports use of functional outcome measures in prion disease. Neurology 77(18):1674-1683.
11. Collinge J, et al. (2009) Safety and efficacy of quinacrine in human prion disease (PRION-1 study): A patient-preference trial. Lancet Neurol 8(4):334-344.
12. Benito-León J (2004) Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 27(4):201-203.
13. Nakajima M, et al. (2004) Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17(3):158-163. (Pubitemid 38339741)
14. Kobayashi Y, Hirata K, Tanaka H, Yamada T (2003) [Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft: An EEG evaluation]. Rinsho Shinkeigaku 43(7):403-408.
15. Geschwind MD, et al. (2013) Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 81(23):2015-2023.
16. Bian J, et al. (2010) Cell-based quantification of chronic wasting disease prions. J Virol 84(16):8322-8326.
17. Barret A, et al. (2003) Evaluation of quinacrine treatment for prion diseases. J Virol 77(15):8462-8469. (Pubitemid 36871474)
18. Mays CE, et al. (2012) Prion inhibition with multivalent PrPSc binding compounds. Biomaterials 33(28):6808-6822.
19. Fasano C, et al. (2008) Gene expression profile of quinacrine-cured prion-infected mouse neuronal cells. J Neurochem 105(1):239-250. (Pubitemid 351441643)
20. Klingenstein R, et al. (2006) Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 98(3):748-759. (Pubitemid 44051276)
21. Ryou C, et al. (2003) Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 83(6):837-843. (Pubitemid 36723692)
22. Browning SR, et al. (2004) Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid PrP. J Virol 78(23):13345-13350. (Pubitemid 39507839)
23. Peretz D, et al. (2001) Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci 10(4):854-863. (Pubitemid 32240511)
24. Saijo E, et al. (2013) Epigenetic dominance of prion conformers. PLoS Pathog 9(10):e1003692.
25. Makarava N, et al. (2011) Genesis of mammalian prions: From non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog 7(12):e1002419.
26. Angers RC, et al. (2010) Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science 328(5982):1154-1158.
27. Collins SJ, et al. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52(4):503-506.
28. Ghaemmaghami S, et al. (2009) Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 5(11):e1000673.
29. Kamatari YO, Hayano Y, Yamaguchi K, Hosokawa-Muto J, Kuwata K (2013) Characterizing antiprion compounds based on their binding properties to prion proteins: Implications as medical chaperones. Protein Sci 22(1):22-34.
30. Georgieva D, et al. (2006) Interactions of recombinant prions with compounds of therapeutical significance. Biochem Biophys Res Commun 344(2):463-470.
31. Vogtherr M, et al. (2003) Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 46(17):3563-3564. (Pubitemid 36988643)
32. Green KM, et al. (2008) Accelerated high fidelity prion amplification within and across prion species barriers. PLoS Pathog 4(8):e1000139.
33. Telling GC, et al. (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274(5295):2079-2082. (Pubitemid 27020700)
34. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (2010) Darwinian evolution of prions in cell culture. Science 327(5967):869-872.
35. Ghaemmaghami S, et al. (2011) Conformational transformation and selection of synthetic prion strains. J Mol Biol 413(3):527-542.
36. Yung L, et al. (2004) Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis 4:53.
37. Berry DB, et al. (2013) Drug resistance confounding prion therapeutics. Proc Natl Acad Sci USA 110(44):E4160-E4169.
38. Zawada Z, et al. (2013) Quinacrine reactivity with prion proteins and prion-derived peptides. Amino Acids 44(5):1279-1292.
39. Dearmond SJ, Bajsarowicz K (2010) PrPSc accumulation in neuronal plasma membranes links Notch-1 activation to dendritic degeneration in prion diseases. Mol Neurodegener 5:6.
40. Spilman P, et al. (2008) A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains. Proc Natl Acad Sci USA 105(30):10595-10600.
41. Huang Y, et al. (2006) Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 34(7):1136-1144.
42. Gayrard V, et al. (2005) A possible pharmacological explanation for quinacrine failure to treat prion diseases: Pharmacokinetic investigations in a ovine model of scrapie. Br J Pharmacol 144(3):386-393. (Pubitemid 40313685)
43. Sandberg MK, Wallén P, Wikström MA, Kristensson K (2004) Scrapie-infected GT1-1 cells show impaired function of voltage-gated N-type calcium channels (Ca(v) 2.2) which is ameliorated by quinacrine treatment. Neurobiol Dis 15(1):143-151. (Pubitemid 38134389)
44. Farrelly PV, et al. (2003) Quinacrine blocks PrP (106-126)-formed channels. J Neurosci Res 74(6):934-941. (Pubitemid 37490427)
45. Turnbull S, Tabner BJ, Brown DR, Allsop D (2003) Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. Neuroreport 14(13):1743-1745. (Pubitemid 37323765)
46. Dohgu S, et al. (2004) Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell Mol Neurobiol 24(2):205-217. (Pubitemid 38481018)
47. Chung E, et al. (2011) Styryl-based and tricyclic compounds as potential anti-prion agents. PLoS ONE 6(9):e24844.
48. Nguyen TH, et al. (2008) Antiprion activity of functionalized 9-aminoacridines related to quinacrine. Bioorg Med Chem 16(14):6737-6746.
49. Nguyen T, Sakasegawa Y, Doh-Ura K, Go ML (2011) Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position. Eur J Med Chem 46(7):2917-2929.
50. Villa V, et al. (2011) Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity. Neurotox Res 19(4):556-574.
51. Tran HN, Bongarzone S, Carloni P, Legname G, Bolognesi ML (2010) Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate protein-protein interactions in prions. Bioorg Med Chem Lett 20(6):1866-1868.
52. Csuk R, et al. (2009) Synthesis of monomeric and dimeric acridine compounds as potential therapeutics in Alzheimer and prion diseases. Arch Pharm (Weinheim) 342(12):699-709.
53. Doh-ura K, et al. (2007) Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine. Cell Mol Neurobiol 27(3):303-316.
54. Dollinger S, Löber S, Klingenstein R, Korth C, Gmeiner P (2006) A chimeric ligand approach leading to potent antiprion active acridine derivatives: Design, synthesis, and biological investigations. J Med Chem 49(22):6591-6595. (Pubitemid 44657453)
55. Sebestík J, Safarík M, Stibor I, Hlavácek J (2006) Acridin-9-yl exchange: A proposal for the action of some 9-aminoacridine drugs. Biopolymers 84(6):605-614.
56. Kocisko DA, Caughey B (2006) Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol 80(2):1044-1046. (Pubitemid 43062916)
57. Murakami-Kubo I, et al. (2004) Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol 78(3):1281-1288. (Pubitemid 38095838)
58. May BC, et al. (2003) Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 100(6):3416-3421. (Pubitemid 36356598)
59. May BC, et al. (2006) Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells. Bioorg Med Chem Lett 16(18):4913-4916. (Pubitemid 44175848)
60. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity. Cancer Res 47(4):943-946. (Pubitemid 17027906)
61. Kang HE, et al. (2012) Characterization of conformation-dependent prion protein epitopes. J Biol Chem 287(44):37219-37232.
62. Angers RC, et al. (2009) Chronic wasting disease prions in elk antler velvet. Emerg Infect Dis 15(5):696-703.